Tigecycline, a glycylcycline-derived antibacterial that has been approved for the treatment of various infections, is widely used for multi-drug resistant bacteria. Coagulopathy is an uncommon side effect during tigecycline treatment and is easily overlooked when it occurs. We reported the effect of tigecycline (50 mg every twelve hours) treatment in an 87-year-old man, with Gram negative bacil...

Multidrug resistance Klebsiella pneumoniae infection is an essential factor threatening the life of patients with severe infection. Polymyxin B widely used in treating multidrug pneumoniae, but few studies on its efficacy and safety. In our study, 205 were admitted to hospital from January 2017 December 2020, treated polymyxin for antibacterial selected as subjects. These divided into two thera...

Tigecycline, a novel, first-in-class glycylcycline antibiotic, has been approved for the treatment of complicated intra-abdominal infections and complicated skin and skin structure infections. The pharmacokinetics, metabolism, and excretion of [(14)C]tigecycline were examined in healthy male volunteers. Tigecycline has been shown to bind to bone; thus, to minimize the amount of radioactivity bi...

Background. Tigecycline is a glycylcycline derived from the tetracycline antibiotics with potent bacteriostatic activity against gram negative, gram positive, and anaerobic organisms. With only 15 to 22 percent of tigecycline excreted unchanged in the urine with a standard dose of 50 mg every 12 hours, clinicians have debated the use of tigecycline for the treatment of multi-drug resistant urin...

BACKGROUND Switch therapy is a management approach combining early discontinuation of intravenous (IV) antibiotics, switch to oral antibiotics, and early hospital discharge. This analysis compares switch therapy using tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia (CAP). METHODS A prospective, randomized, double-blind, Phase 3 clinical trial; patien...

Multidrug-resistant Klebsiella pneumoniae strains that produce a serine carbapenemase (KPC) are emerging worldwide, with few therapeutic options that retain consistent susceptibility. The objective of this study was to determine the effect of combination therapy with tigecycline versus tigecycline alone against KPC-producing isolates (KPC isolates). An in vitro pharmacodynamic model was used to...

OBJECTIVES To examine the incidence of pancreatitis among subjects enrolled in the tigecycline clinical trial programme, summarize cases and examine concomitant use of other pancreatitis-causing medications. METHODS Subject data from Phase 3 and 4 comparative tigecycline studies were included in the analysis; investigator-reported adverse events of 'pancreatitis', 'necrotizing pancreatitis' o...

BACKGROUND On the basis of noninferiority trials, tigecycline received Food and Drug Administration (FDA) approval in 2005. In 2010, the FDA warned in a safety communication that tigecycline was associated with an increased risk of death. METHODS PubMed, EMBASE, Scopus, and ClinicalTrials.gov were searched using the terms "tigecycline" and "randomized controlled trial (RCT)" through April 201...

Tigecycline is a broad-spectrum glycylcycline antibiotic with potent in vitro activity against Clostridium difficile. We used a mouse model to test the hypothesis that tigecycline has a low propensity to promote colonization and toxin production by C. difficile due to inhibitory activity in the colon. Mice (5 to 8 per group) received subcutaneous injections of tigecycline (low and high doses) a...

The activities of tigecycline and eight other agents were evaluated against 220 coryneform bacteria and 42 Listeria monocytogenes isolates. All strains were inhibited by tigecycline at 0.5 mug/ml, except for 11 Corynebacterium striatum strains that were inhibited at 1 mug/ml. Tigecycline shows good in vitro activity against coryneform bacteria and L. monocytogenes.